/
FBLG
$1.14+$0.04 (+3.60%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$7.4M
7M shares
52-week range
$0.62 – $12.80
4% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-580.85
FibroBiologics, Inc. Common Stock
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
www.fibrobiologics.com- Employees
- 15
- IPO / List date
- Jan 31, 2024
- HQ
- HOUSTON, TX
Held by traders on TradeandTell
No one on the platform currently holds FBLG.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 15,997 | $21.1K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-03-30 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded FBLG yet.
